Clinical implications of AGBL2 expression and its inhibitor latexin in breast cancer by Hao Zhang et al.
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
Zhang et al. World Journal of Surgical Oncology 2014, 12:142
http://www.wjso.com/content/12/1/142RESEARCH Open AccessClinical implications of AGBL2 expression and its
inhibitor latexin in breast cancer
Hao Zhang1, Yuan Ren2, Deyan Pang3 and Caigang Liu1*Abstract
Background: We investigated the expression status of AGBL2 and its inhibitor latexin in breast cancer stem cells
and its clinical implications in order to lay a foundation for managing breast cancer.
Methods: CD44+/CD24- tumor cells (CSC) from clinical specimens were sorted using flow cytometry. AGBL2
expression status was detected in CSC and 126 breast cancer specimens by western blot and
immunohistochemistry staining. The relationship between the AGBL2 protein and clinicopathological parameters
and prognosis was subsequently determined.
Result: As a result, CSC are more likely to generate new tumors in mice and cell microspheres that are deficient in
non-obese diabetic/severe combined immunodeficiency mice (NOD/SCID) compared to the control group. The AGBL2
protein was expressed higher in CSC induced to epithelial to mesenchymal transition (EMT) when compared to the
control cells, and was found to be related to CSC chemotherapy resistance. After Spearman regression correlation
analysis, AGBL2 was observed to be related to clinical stage, histological stage, and lymph node metastasis. In the Cox
regression test, the AGBL2 protein was detected as an independent prognostic factor. Through immunoprecipitation,
AGBL2 and latexin could form immune complexes.
Conclusions: These results demonstrate that AGBL2 is a latexin-interacting protein that regulates the tubulin tyrosination
cycle and is a potential target for intervention.
Keywords: Breast cancer, Cancer stem cell, AGBL2, latexin, SurvivalBackground
Breast cancer is the most common cause of death of all
female malignant tumor diseases [1]. In 2008, 1,380,000
new occurrences of breast cancer were diagnosed world-
wide, with 458,400 persons dying from breast cancer
that same year [2,3].
Stem cells, which represent only a very small percent-
age of the total tumor mass, have been found to be the
source of some, and possibly most, cancers [4]. Breast can-
cer stem cells are a small group of tumor cells with the
capacity to self-renew, a strong ability to form solid breast
tumors, and the ability to differentiate into a relatively qui-
escent primitive group of cancer cells that are considered
the underlying factor of tumor recurrence and the main
reason that breast cancers resist therapies [5].* Correspondence: caigang_liu@126.com
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reproduction in any medium, provided the orAGBL2 is a cytoplasmic carboxypeptidase. Knockdown
of AGBL2 results in a failure of the cell to detyrosinate the
C-terminal EEY region of α-tubulin, and indicates that it is
a candidate for the long sought after tubulin tyrosine car-
boxypeptidase important in regulation of microtubule dy-
namics [6]. Retinoic acid receptor responder 1 (RARRES1),
also known as tazarotene-induced gene 1 (TIG1), was first
identified as a novel retinoid-responsive gene in skin. Not-
ably, a RARRES1 family member, latexin, was initially de-
scribed as the only known mammalian carboxypeptidase
inhibitor and is involved in the regional specification of
neurons [7-10]. Despite extensive evidence for the tumor
suppressor role of RARRES1, no mechanism for its bio-
logical function has been determined.
AGBL2 is reported to be involved in tumor epithelial
to mesenchymal transition (EMT), but the mechanism
by which it operates is still unclear [6]. Currently, theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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(CSC) and the clinical implications for breast cancer are
also unclear. In the present study, we try to sort and
identify breast cancer stem cells investigate the expres-
sion status of AGBL2 in those cells, and evaluate the
clinical implications of AGBL2 in breast cancer. Gaining
this knowledge will lay a foundation for managing breast
cancer.
Methods
Patients and tissue specimens
A total of 126 patients who had histologically confirmed
breast cancer and who underwent radical operations in
China Medical University between January 2001 and
January 2006 were enrolled for immunohistochemical
and immunofluorescence double staining and prognostic
analysis. The mean age was 50.73 ± 10.28 years (range from
27 to 80 years). The criteria to include a patient in this
study were as follows: (1) curative operations (modified
radical mastectomy plus axillary lymph node dissection)
were performed; (2) resected specimens were pathologic-
ally examined; (3) more than 10 lymph nodes were patho-
logically examined after the operation; and, (4) a complete
medical record including the estrogen receptor (ER), pro-
gesterone receptor (PR), human epidermal growth factor
receptor 2 (Her2), tumor protein P53 (p53), and antigen
Ki67 (Ki67) status was available. The study protocol
was approved by the Ethics Committee of China Medical
University and written informed consent was obtained
from all participants involved in the study.
Identifying the ability of cancer stem cells to form tumors
The clinical specimens were digested into single tumor
cells using collagenase III (Boster, Wuhan, China). The
tumor cells were suspended in 100 μl/106 cells of Hank’s
balanced salt solution (HBSS) with 2% heat-inactivated
calf serum (HICS). The samples were then washed
twice with HBSS/2% HICS and suspended. Antibodies,
including anti-CD2, −CD3 -CD10, −CD16, −CD18, −CD31,
and anti-CD326 were added and incubated on ice for
20 minutes and then washed twice with HBSS/2%
HICS. Lineage + cells were first eliminated using anti-
CD2, −CD3 -CD10, −CD16, −CD18, −CD31, and anti-
CD326 during flow cytometry. Dead cells were eliminated
using the viability dye 7AAD (Boster, Wuhan, China).
Next, CD44+/CD24- tumor cells were sorted by CD44
and CD24 in flow cytometry. The selected cells to be
injected were then suspended in a 1640/Matrigel mix
(1:1 volume) (Boster, Wuhan, China) and injected into
the appropriate area of the mammary fat pad.
Mammosphere generation test
For this step, complete MammoCult™ medium (human)
(Boster, Wuhan, China) was prepared by adding 50 mL ofthawed MammoCult™ proliferation supplements (human)
(Boster, Wuhan, China) to 450 mL of MammoCult™ basal
medium (human). Single cells were plated on ultralow at-
tachment plates (Corning, Acton, Massachusetts, United
States) in the complete MammoCult™ medium at a density
of 20,000 viable cells/mL. The number of spheres for each
well was evaluated after seven days of culture.
siRNA transfection and the effect confirmation
AGBL2 siRNA and control siRNA were designed and
synthesized by Wanlei Biotechnology, Inc (Shenyang,
China). The downregulation of AGBL2 by siRNA was
confirmed by RT-PCR and western blot at the indicated
time points.
Transfection and stable colony selection
Transfection was performed using the transfection re-
agent Lipofectamine™ 2000 (Invitrogen) (Boster, Wuhan,
China) based on the manufacturer’s instructions. The
clones derived from breast cancer cells stably expressing
latexin were selected for further experiments.
Treatments with chemotherapeutic agents and measuring
cell viability
When the above cells, cultured as monolayers, were
healthy and were 80 to 90% confluent, they were washed
with warm HBSS. The cells were scraped gently from
the dish using a sterile cell scrape. The scraped cells were
then resuspended in complete MammoCult medium and
counted. The sensitivity of the cells to three chemothera-
peutic drugs were examined using the cell counting kit-8
(CCK-8) (Boster, Wuhan, China) technique. Cells were
plated at a density of 5 × 104/mL cells per well into ultra-
low attachment 96-well plates containing 100 μl complete
MammoCult medium and treated with a concentration of
cisplatin (DDP) (2.5 μg/ml/PPC (plasma peak concentra-
tion)), epirubicin (EPI) (0.78 μg/ml/PPC), and docetaxel
(DTX) (3.7 μg/ml/PPC) as follows: 0.2, 1.0, 5.0, 10.0 PPC.
CCK-8 reagent was added to each well and incubated for
two hours before reading at wavelength of 450 nm. The
cells were counted at 48 and 72 hours with CCK-8.
Western blot analysis
For western blot analysis, the cells were lysed with the buf-
fer [0.1% sod dodecyl sulfate (SDS), 50 mmol/L Tris Hydro-
chloride (Tris–HCl) (ph 7.6), 1% NP-40, 150 mmol/L NaCl,
2 mg/ml aprotinin, 2 mg/ml leupeptin and 7 mg/ml
phenylmethanesulfonyl fluoride (PMSF)]. The protein
concentrations were determined using the bicinchoninic
acid (BCA) protein assay kit (Pierce Biotechnology Inc.,
Rockford, Illinois, United States). Thirty micrograms of
protein were separated on 10% SDS-PAGE gels and trans-
ferred to a polyvinylidene fluoride (PVDF) membrane.
After blocking, the membrane was incubated with anti-
Figure 1 AGBL2 protein was expressed significantly higher in breast cancer tissues (B) compared to paracancerous tissue and atypical
hyperplasia tissues (A).
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Kingdom) at 4°C overnight. After washing, the membrane
was incubated with a secondary antibody at a dilution
1:2,000 at room temperature for one hour. Proteins were
detected with the electrochemiluminescence (ECL) kit
(Varsal Instruments, Beijing, China), and anti-β-actin anti-
body (Sigma-Aldrich, St. Louis, Missouri, United States)
was used as a loading control. Densitometry was per-
formed by Gel-pro Analyze software (Media Cybernetics,
Silver Spring, Maryland, United States).Table 1 Correlations between AGBL2 expression and
clinicopathological features (n = 126)
Variables N AGBL2− AGBL2+ P value
Age 0.062
<35 Y 18 14 4
>35 Y 108 60 48
Tumor size 0.562
T1 24 16 8
T2 83 46 37
T3 19 12 7
Clinical stage 0.001
I 15 14 1
II 57 45 12
III 54 15 39
Tumor stage 0.151
DCIS 16 7 9
IDC 110 67 43
Metastatic nodes 0.006
Negative 50 38 12
Positive 76 36 40
Her2 status 0.632
Positive 21 9 12
Negative 105 47 58Immunohistochemistry experimental procedures
To score AGBL2 as immuno-positive staining, the posi-
tive cells appeared as a yellow to brown color in the nu-
cleus and/or cytoplasm. AGBL2 expression was classified
qualitatively according to intensity of staining and semi-
quantitatively according to the following criteria: mild/
0 if <1% of neoplastic cells discretely expressed AGBL2;
intermediate/1+ if ≥1 and <10% of morphologically un-
equivocal neoplastic cells discretely expressed AGBL2;
and strong/2+ if ≥10% of morphologically unequivocal
neoplastic cells discretely expressed AGBL2. Samples
stained intermediate or strong or scored as 1+ or 2+
were considered positive.
Tumor growth factor-β1 (TGF-β1) stimulation
Breast cancer stem cells were plated at 4 × 104 cells per
35 mm cell culture dish, and 10 ng/ml recombinant hu-
man tumor growth factor-β1 (TGF-β1) (R&D Systems,
United States) or vehicle (4 mM HCl and 0.1% albumin
from bovine serum (BSA)) was added to the media. Cells
were passaged after three days in culture, and TGF-β
was replenished. Cells were stimulated for a total of six
days before using.
Immunoprecipitation
Breast cancer cells were lysed using a radio-immuno-
precipitation assay (RIPA) buffer and centrifuged atTable 2 Spearman correlation analysis between
clinicopathological features and AGBL2
Clinicopathological features AGBL2 expression
(P; Spearman correlation)
Age 0.076 (0.071)
Tumor size 0.053 (0.083)
Clinical stage 0.007 (0.157)
Histological stage 0.036 (0.121)
Lymph node metastasis 0.001 (0.184)
Her2 status 0.086 (0.036)
Table 3 Multivariate analysis of the factors related to
postoperative distant metastasis
Characteristic Exp(B) 95% CI for Exp(B) P value
Age 0.553 0.267-2.292 0.371
Tumor size 1.978 1.176-4.126 0.003
Clinical stage 3.936 1.774-6.882 0.001
Tumor stage 2.217 0.557-7.826 0.072
Lymph node metastasis 4.376 2.287-8.762 0.000
Her-2 status 1.549 0.736-3.472 0.059
AGBL2 1.517 1.073-3.432 0.031
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ered and pre-cleared by adding 1 μg of normal immuno-
globulin G (IgG) premixed with 20 μL of A/G protein-
bead slurry. The mixture was incubated for 30 minutes
at 4°C and then centrifuged at 1,000 × g for 5 minutes.
The supernatant was recovered and mixed with 10 μL of
primary antibody and incubated for 1 hour at 4°C. A
total of 20 μL of A/G protein-bead slurry was then
added and incubated at 4°C for 1 hour. Samples were
then centrifuged and supernatants were discarded. The
precipitate was boiled for 3 minutes after adding 20 μL
of SDS-PAGE sample buffer to release the complex from
the beads. Western blotting was then performed as de-
scribed above.
Statistical analysis
All data were analyzed with SPSS Statistics software
(Version 13.0, Chicago, Illinois, United States). Relationships
between AGBL2 and other parameters were studied
using the chi-square test, Fisher’s extract test, or inde-
pendent t tests. Disease-specific survival was analyzed
using the Kaplan-Meier method. The log-rank test was
used to analyze survival differences. Multivariate ana-
lysis was performed using the Cox proportional hazards
model selected in forward stepwise. A P value of less
than 0.05 was considered statistically significant.Figure 2 Survival curves about clinical stage (A), lymph node metastaResults
AGBL2 expression in breast cancer and its relationship
with clinicopathological characteristics
Breast cancer tissues, paracancerous tissues, and atypical
hyperplasia tissues were all from the same patients. Tis-
sue samples were stained with hematoxylin and eosin to
determine the histological type and tumor grade. Immu-
nohistochemical examination showed that AGBL2 was
located in the cytoplasm and membrane of the breast
cancers (Figure 1). It was also observed that the AGBL2
protein was expressed significantly higher in breast can-
cer tissues when compared to paracancerous and atypical
hyperplasia tissues (28.63% versus 4.32% versus 2.91%, re-
spectively) (Figure 1A and 1B). The cases with high AGBL2
expression tended to develop into lymph node and postop-
erative distant metastasis (Table 1).
Spearman correlation regression analysis showed that
AGBL2 expression has a linear correlation to histological
stage, lymph node metastasis, and clinical stage (P = 0.036,
0.001, and 0.007, respectively) (Table 2). After multivariate
analysis, the clinical stage, lymph node metastasis, tumor
size, and AGBL2 expression were related to postoperative
distant metastasis (P = 0.001, 0.000, 0.003, and 0.031, re-
spectively) (Table 3).Prognostic analysis
The prognostic analysis showed that AGBL2, along with
clinical stage, and lymph node metastasis, were significantly
associated with a poorer disease-specific survival (P = 0.007,
0.002, and 0.004, respectively) (Figure 2).Effects of AGBL2-siRNA or latexin on proliferation and
invasiveness of breast cancer cells
The methylthiazolyldiphenyl-tetrazolium bromide (MTT)
analysis result showed that the proliferation of breast can-
cer cells was significantly inhibited by AGBL2-siRNA.
We next examined the effect of AGBL2-siRNA and
latexin on invasion in breast cancer cells using thesis (B), and AGBL2 expression (C).
Figure 3 Cells exposed to AGBL2-siRNA or Latexin decreased among the three drugs when compared with the control (DDP: cisplatin,
EPI: epirubicin, DTX: docetaxel, MTT: methylthiazolyldiphenyl-tetrazolium bromide, h: hours).
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vasiveness of breast cancer cells was decreased.AGBL2 downregulation or latexin upregulation sensitizes
to chemotherapy drugs in cancer stem cells
To investigate whether downregulation of AGBL2 ex-
pression or upregulation of latexin expression has the
potential to sensitize CSC to chemotherapy, a combin-
ation treatment of AGBL2-specific siRNA or upregula-
tion of latexin with chemotherapy drugs was performed.
Twenty-four hours after transfection with siRNA, cells
were treated with DDP, EPI, and DTX at 0, 0.2 PPC, 1
PPC, 5 PPC and 10 PPC scaled concentrations for 48
and 72 hours. The half maximal inhibitory concentration
(IC50) was determined by the MTT assay. Figure 3
shows that the cells exposed to AGBL2-siRNA or latexinFigure 4 AGBL2 and Latexin could form immune complexes throughshowed a significant decrease in IC50 among the three
drugs when compared with the control (P <0.01).
AGBL2 and latexin expression in breast cancer stem cells
that have been induced to EMT
By microarray analysis, we analyzed ten cases, including
breast cancer stem cells induced to EMT by TGF-β1
and those not induced. We found that the expression
level of AGBL2 significantly increased in breast cancer
stem cells induced to EMT, as opposed to those that
were latexin decreased.
Identification of the interactome between AGBL2 and
latexin
The presence of AGBL2 in the exogenously- and
endogenously-expressed latexin complex was confirmed
using western blot after tandem affinity purificationimmunoprecipitation (MW: Molecular Weight).
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immunoprecipitation. The immunoblot showed the pres-
ence of latexin and AGBL2 present in the latexin-pGlue
complex after tandem affinity purification, latexin en-
dogenous immunoprecipitation, and AGBL2 endogenous
immunoprecipitation (Figure 4). These results demon-
strate that AGBL2 is a latexin-interacting protein that reg-
ulates the tubulin tyrosination cycle and that it is a
potential target for intervention.
Discussion
Tumor stem cells have been found to be the source of
most cancers and the culprit of tumor recurrence, me-
tastasis, and drug resistance [11]. In a recent study,
AGBL2 was reported as a bridge between cancer stem
cell and metastasis [6]. No studies to date, however, have
examined the relationship among AGBL2 expression sta-
tus and breast cancer chemotherapy sensitivity, and the
clinical implications of breast cancer. In the current
study, we sorted and identified the breast cancer CSC
from clinical specimens, observing that AGBL2 was highly
expressed in breast cancer CSC induced to EMT when
compared to the control group. Moreover, drug sensitivity
tests showed that a combination treatment of AGBL2-
specific siRNA with chemotherapy drugs could signifi-
cantly increase the apoptosis of breast cancer CSC. The
outcome demonstrated that AGBL2 plays an important
role in breast cancer’s resistance to chemotherapy.
We also investigated the relationship between AGBL2
expression and the biological behavior of breast cancer
CSC and the clinicopathological characteristics of breast
cancer. The AGBL2 protein was observed to be expressed
significantly higher in cancerous tissues than tumor-
adjacent tissues. Moreover, AGBL2 protein was found to
be related to clinical stage, histological stage, and lymph
node metastasis.
After survival analysis, AGBL2 was shown to attain a
significantly poorer postoperative disease-specific sur-
vival. Indeed, the Cox regression test showed that the
AGBL2 protein was detected as an independent prog-
nostic factor. These outcomes suggest that AGBL2 is as-
sociated with breast cancer CSC.
In a previous study, Ke et al. [12] identified high levels
of Latexin expression in an immortalized human gastric
epithelium cell line, GES-1, as compared to expression
in the MNNG-transformed GES-1 cells (MC) cell line,
which is the malignant derivative of the GES-1 cell line.
These findings suggest that downregulation of latexin
expression is correlated with malignant transformation
of immortalized human gastric epithelial cells.
Here, we demonstrated that AGBL2 may also play a
role in breast cancer metastasis and may be a potential
biomarker for the metastasis and chemotherapy resist-
ance of breast cancer.Conclusions
The present study found that AGBL2 was highly
expressed in CSC and could be a potential biomarker for
the lymph node metastasis and chemotherapy resistance
of breast cancer tumors. The underlying genetic mech-
anism of AGBL2 and its inhibitor latexin in regulating
the breast cancer CSC is still unclear and needs further
investigation.
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